Jun 30, 2025, 06:07
Top Biotechs at ASCO: Michelle Xia on Building Akeso and Advancing Dual-Target Immunotherapy
In this episode of Top Biotechs at ASCO, recorded at ASCO 2025, Dr. Michelle Xia, Founder and CEO of Akeso Biopharma, shares the remarkable journey of building one of China’s leading biopharma companies. Founded in 2012 with just four people, Akeso has grown into a fully integrated company with over 3,400 employees across drug discovery, development, manufacturing, and commercialization.
Akeso is a global leader in bispecific antibody innovation, with two bispecifics—Cadonilimab (PD-1/CTLA-4) and Ivonescimab (VEGF/PD-1)—already commercialized in China. Cadonilimab has received approval for cervical and gastric cancers, and data from its use in first-line cervical cancer was highlighted in an oral presentation at ASCO 2025.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 19, 2025, 20:00
Jul 19, 2025, 19:47
Jul 19, 2025, 19:13
Jul 19, 2025, 18:12
Jul 19, 2025, 17:49